Clinical-stage biopharma Ovid Therapeutics and biotech Nuvation Bio rated "Strong Buy" by analysts

From Yahoo Finance: 2025-06-20 14:25:00

Ovid Therapeutics, a small clinical-stage biopharmaceutical company with a market capitalization of $21 million, is focusing on developing treatments for rare neurological disorders such as epilepsy. Despite falling 67.6% YTD, analysts rate OVID stock a “Strong Buy.” Ovid’s pipeline includes OV329, a promising epilepsy treatment candidate awaiting Phase 1 trial results in Q3 2025.

Nuvation Bio, a clinical-stage biotech company with a $609 million market cap, is developing targeted oncology treatments for challenging cancers like breast, ovarian, and lung cancer. NUVB stock is down 27.7% YTD, but its lead candidate, taletrectinib, has already been approved in China and the U.S. Analysts rate NUVB stock a “Strong Buy” with a target price suggesting a 258% rally over the next 12 months.



Read more at Yahoo Finance: Are These 2 ‘Strong Buy’ Rated Growth Stocks Buys Right Now?